Plasma Levels of Advanced Glycation Endproducts and Risk of Cardiovascular Events: Findings From 2 Prospective Cohorts

Background Advanced glycation endproducts (AGEs) have been linked to cardiovascular disease (CVD) in cohorts with and without diabetes. Data are lacking on prospective associations of various α‐dicarbonyl‐derived AGEs and incident CVD in the general population. We tested the hypothesis that major plasma AGEs are associated with new‐onset CVD in 2 population‐based cohorts of differing age and comorbidities. Methods and Results Analyses involved a random subcohort (n=466) from the Cardiovascular Health Study and a case‐cohort sample (n=1631) from the Multi‐Ethnic Study of Atherosclerosis. Five AGEs and 2 oxidative products were measured by liquid chromatography tandem mass spectrometry. Associations with CVD (myocardial infarction and stroke) were evaluated with Cox regression. Participants in the Cardiovascular Health Study were older than the Multi‐Ethnic Study of Atherosclerosis, and had more comorbidities, along with higher levels of all AGEs. During median follow‐up of 11 years, 439 participants in the Multi‐Ethnic Study of Atherosclerosis and 200 in the Cardiovascular Health Study developed CVD. After multivariable adjustment, carboxymethyl‐lysine, 3‐deoxyglucosone hydroimidazolones and a summary variable of all measured AGEs (principal component 1) were significantly associated with incident CVD in the Cardiovascular Health Study (HRs [95% CI]: 1.20 [1.01, 1.42], 1.45 [1.23, 1.72], and 1.29 [1.06, 1.56], respectively), but not the Multi‐Ethnic Study of Atherosclerosis. Oxidative products were not associated with CVD in either cohort. Conclusions We found α‐dicarbonyl‐derived AGEs to be associated with CVD in an older cohort, but not in a healthier middle‐aged/older cohort. Our results suggest that AGEs may exert detrimental cardiovascular effects only under conditions of marked dicarbonyl and oxidative stress. Further investigation of α‐dicarbonyl derivatives could lead to potential new strategies for CVD prevention in high‐risk older populations.

[1]  P. Kapahi,et al.  The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. , 2018, Cell metabolism.

[2]  Y. van der Graaf,et al.  Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes , 2018, Diabetes Care.

[3]  Paul J Thornalley,et al.  Advanced glycation end products in the pathogenesis of chronic kidney disease. , 2018, Kidney international.

[4]  A. Saremi,et al.  Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes , 2017, Diabetes Care.

[5]  P. Formanowicz,et al.  Advanced Oxidation Protein Products and Carbonylated Proteins as Biomarkers of Oxidative Stress in Selected Atherosclerosis-Mediated Diseases , 2017, BioMed research international.

[6]  H. Parving,et al.  Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study , 2017, Diabetes.

[7]  Kevin M. Wheelock,et al.  Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes , 2016, Diabetes.

[8]  Paul J Thornalley,et al.  Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. , 2015, Biochemical and biophysical research communications.

[9]  R. H. Khan,et al.  3-Deoxyglucosone: A Potential Glycating Agent Accountable for Structural Alteration in H3 Histone Protein through Generation of Different AGEs , 2015, PloS one.

[10]  B. Psaty,et al.  Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. , 2014, Atherosclerosis.

[11]  Michael E. Miller,et al.  Early Progression of Diabetic Nephropathy Correlates With Methylglyoxal-Derived Advanced Glycation End Products , 2013, Diabetes Care.

[12]  M. Huijberts,et al.  Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. , 2013, The Journal of clinical endocrinology and metabolism.

[13]  V. Monnier,et al.  Molecular Basis of Arterial Stiffening: Role of Glycation – A Mini-Review , 2012, Gerontology.

[14]  Paul J Thornalley,et al.  Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity , 2011, Diabetes.

[15]  H. Parving,et al.  Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes , 2011, Diabetes Care.

[16]  Paul J Thornalley,et al.  Protein damage in diabetes and uremia—identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect , 2011, Free radical research.

[17]  S. Bandinelli,et al.  Plasma Carboxymethyl‐Lysine, an Advanced Glycation End Product, and All‐Cause and Cardiovascular Disease Mortality in Older Community‐Dwelling Adults , 2009, Journal of the American Geriatrics Society.

[18]  Moyses Szklo,et al.  Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2008, Archives of internal medicine.

[19]  M. Laakso,et al.  Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study , 2007, Diabetologia.

[20]  Paul J Thornalley,et al.  Advanced glycation endproducts: what is their relevance to diabetic complications? , 2007, Diabetes, obesity & metabolism.

[21]  L. Kuller,et al.  10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. , 2006, Archives of internal medicine.

[22]  R. Nelson,et al.  α-Oxoaldehyde metabolism and diabetic complications , 2003 .

[23]  Anne Dawnay,et al.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. , 2003, The Biochemical journal.

[24]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[25]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[26]  L H Kuller,et al.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. , 1995, Annals of epidemiology.

[27]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[28]  T. W. Anderson.  ASYMPTOTIC THEORY FOR PRINCIPAL COMPONENT ANALYSIS , 1963 .